In Vitro Tissue Model of Psoriasis

Information

  • Research Project
  • 7939715
  • ApplicationId
    7939715
  • Core Project Number
    R44AR052982
  • Full Project Number
    5R44AR052982-03
  • Serial Number
    52982
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    12/15/2004 - 20 years ago
  • Project End Date
    8/31/2012 - 12 years ago
  • Program Officer Name
    CIBOTTI, RICARDO
  • Budget Start Date
    9/1/2010 - 14 years ago
  • Budget End Date
    8/31/2012 - 12 years ago
  • Fiscal Year
    2010
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/19/2010 - 14 years ago
Organizations

In Vitro Tissue Model of Psoriasis

DESCRIPTION (provided by applicant): Psoriasis is a chronic, inflammatory, hyper-proliferative skin disease that affects nearly 80 million people worldwide. During Phase 1, cells from involved psoriatic lesions were harvested, proliferated in monolayer culture, and cryopreserved. Culture conditions were identified which allowed the production of a full thickness psoriatic tissue model (PTM). The PTM had a hyperproliferative phenotype, produced cytokines known to be important in the psoriatic disease state, and expressed protein markers characteristic of psoriasis. In addition, the PTM appeared responsive to cytokine treatments known to be effective in treating psoriasis. Phase II research will expand on Phase 1 results. The full-thickness 3-dimensional PTM will be further developed by incorporating immuno-competent T cells. The tissue model will be fully characterized in terms of gene expression and cytokine release and the effect of immuno- suppressive drugs will be investigated. Finally, culture conditions will be adapted to allow production of the PTM in a high throughput screening (HTS) format that is compatible with modern HTS drug screening methods. PUBLIC HEALTH RELEVANCE: In order to perform relevant basic research and drug discovery experiments, it is essential to have relevant disease models. The availability of an in vitro reconstructed, immuno-competent psoriatic tissue model will fulfill the needs of pharmaceutical companies and the academic institutions working in the field of psoriasis.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R44
  • Administering IC
    AR
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    436471
  • Sub Project Total Cost
  • ARRA Funded
    True
  • CFDA Code
    701
  • Ed Inst. Type
  • Funding ICs
    NIAMS:436471\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MATTEK CORPORATION
  • Organization Department
  • Organization DUNS
    147365936
  • Organization City
    ASHLAND
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    017211717
  • Organization District
    UNITED STATES